Welcome to our dedicated page for Asensus Surgical news (Ticker: ASXC), a resource for investors and traders seeking the latest updates and insights on Asensus Surgical stock.
Asensus Surgical, Inc. (NYSE American: ASXC) is a trailblazing medical device company that enhances minimally invasive surgery through digital laparoscopy. The company's flagship product, the Senhance® Surgical System, is the first machine vision system used in robotic surgery. It leverages augmented intelligence, connectivity, and robotics to address clinical, cognitive, and economic challenges in surgery.
Headquartered in Research Triangle Park, North Carolina, Asensus Surgical focuses exclusively on the research, development, and sale of medical device robotics aimed at improving surgical outcomes. The company's cutting-edge technology includes the Intelligent Surgical Unit™ that brings augmented intelligence into the operating room. One of its latest innovations is the LUNA™ Surgical System, a next-generation robotic and instrument system under development.
Committed to global healthcare improvements, Asensus Surgical has expanded its reach with the Senhance System now available in the US, EU, Japan, Russia, and select other countries. The system has recently been adopted by Nagoya University Hospital in Japan, dedicated to pediatric procedures. This marks a significant milestone, as the Senhance System offers specialized instrumentation and advanced clinical intelligence, aimed at reducing invasiveness and increasing precision in pediatric surgery.
In a recent strategic move, Asensus Surgical entered into a definitive merger agreement with KARL STORZ Endoscopy-America, Inc., a subsidiary of KARL STORZ SE & Co. KG. This merger, valued at $0.35 per share, is anticipated to enhance KARL STORZ's portfolio and market presence, particularly in the robotic surgical market. The transaction has been unanimously approved by Asensus’ Board of Directors and is expected to close during the third quarter of 2024.
Asensus Surgical continues to be driven by collaboration and human ingenuity, striving to make surgery more accessible and predictable while delivering consistently superior outcomes. For more detailed information, visit www.asensus.com.
Asensus Surgical (AMEX: ASXC) announced that Hirosaki University Hospital in Japan has signed an agreement to lease a Senhance Surgical System. This addition aims to enhance the hospital's Robotic Surgery Program. The CEO, Anthony Fernando, expressed confidence in expanding their presence in Japan and highlighted the Senhance platform's unique features, including the world's smallest surgical instruments and advanced machine learning capabilities. This marks a significant step in advancing innovative surgical options for physicians and patients.
Asensus Surgical (NYSE American: ASXC) announced that Paul LaViolette, Board Chair since 2013, will step down in late October due to professional commitments. David Milne, an existing board member, will succeed him. LaViolette praised the company’s evolution, emphasizing the potential of Performance-Guided Surgery and the Senhance Surgical System. Milne, experienced in medical technology, expressed honored to lead Asensus during its critical market development phase.
Asensus aims to transform surgery through digital innovation and enhanced surgeon control.
Asensus Surgical, Inc. (NYSE American: ASXC) has announced a partnership with
Asensus Surgical, Inc. (ASXC) has announced that Loginov Moscow Clinical Scientific Center is the first Russian facility to implement the Senhance Surgical System. This robotic surgery program aims to enhance minimally invasive surgical options for patients. The Senhance platform integrates augmented intelligence, offering features such as haptic feedback and eye-tracking control. Loginov Moscow, a prominent institution with 48 medical departments and over 13,000 annual operations, intends to improve surgical outcomes through this advanced technology.
Asensus Surgical, Inc. (ASXC) announced that Anthony Fernando, CEO, and Shameze Rampertab, CFO, will present at three virtual investor conferences. The events include:
- H.C. Wainwright 23rd Annual Global Investment Conference: Recorded presentation available from September 13, 2021.
- Baird 2021 Global Healthcare Conference: Live presentation on September 14, 2021, at 2:35 PM ET.
- 2021 Cantor Virtual Global Healthcare Conference: Live presentation on September 28, 2021, at 1:20 PM ET.
Asensus Surgical has received FDA 510(k) clearance for enhanced machine vision capabilities on its Intelligent Surgical Unit™ (ISU™), expanding its digital surgery features. This upgrade includes 3D measurement, digital tagging, image enhancement, and improved camera control, all crucial for soft-tissue abdominal surgery. The ISU works alongside the Senhance® Surgical System, enhancing surgeon efficiency and precision. This is a significant step in Performance-Guided Surgery™, aiming to achieve superior surgical outcomes.
Asensus Surgical, Inc. (ASXC) reported its second-quarter 2021 results, highlighting significant growth in surgical procedures and revenue. The company performed over 1,000 procedures in the first half of 2021, a 175% increase year-over-year. Revenue rose to $1.1 million, up from $0.7 million a year ago, attributed to system sales, instruments, and services. The firm received FDA clearance for 5 mm articulating instruments, enhancing its Senhance Surgical System. Although net loss narrowed to $13.2 million, expenses increased to $14.8 million. Asensus aims to install 10-12 new systems in 2021.
Asensus Surgical (NYSE American: ASXC) has received FDA 510(k) clearance for 5 mm articulating instruments, enhancing its Senhance Surgical System. This addition allows for improved access during surgeries, offering two additional degrees of freedom. Previously granted a CE Mark in the EU, these instruments aim to expand clinical utility and surgical performance. The Senhance system stands out through its use of augmented intelligence, machine learning, and haptic feedback, setting a new standard in Performance-Guided Surgery.
Asensus Surgical, Inc. (NYSE American: ASXC) has expanded its Board of Directors by appointing Elizabeth Kwo, MD, and Kevin Hobert, effective immediately. Dr. Kwo brings expertise in healthcare technology and predictive analytics, while Hobert has a rich background in medical technology leadership. Both are expected to enhance Asensus’s efforts in advancing the Senhance Surgical System, aimed at revolutionizing digital surgery. Chairman Paul LaViolette emphasized their skills align with the company's vision for Performance-Guided Surgery.
Asensus Surgical, Inc. (ASXC) will release its second quarter financial and operating results on August 5, 2021, after market close. A conference call to discuss these results will begin at 4:30 p.m. ET, available via telephone and webcast. Asensus is focused on Performance-Guided Surgery, utilizing its Senhance® Surgical System and Intelligent Surgical Unit™ to enhance surgical outcomes and reduce variability. The system features advanced technologies such as machine vision and deep learning, aiming to transform surgery and healthcare value.
FAQ
What is the current stock price of Asensus Surgical (ASXC)?
What is the market cap of Asensus Surgical (ASXC)?
What does Asensus Surgical, Inc. do?
Where is Asensus Surgical headquartered?
What is the Senhance® Surgical System?
What is the latest innovation from Asensus Surgical?
In which regions is the Senhance® Surgical System available?
Has Asensus Surgical recently partnered with any hospitals?
What is the merger agreement with KARL STORZ about?
When is the merger with KARL STORZ expected to close?
Will Asensus Surgical continue to be publicly traded after the merger?
How can I learn more about Asensus Surgical's products?
